Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine in Chronic Beryllium Disease
NCT01088243Phase 2Completed
- Sponsor
- National Jewish Health
- Start
- Mar 2010
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Salcrozine in Chronic beryllium disease (CBD), sponsored by National Jewish Health. Started Mar 2010; status: completed.
02
Drugs
Salcrozine
03
Conditions
Chronic beryllium disease (CBD)
Beyond the preview
Go deeper on NCT01088243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01088243.